May 12, 2022. Clinical benefits should remain the key endpoints for approval decisions of these treatments. Surrogate endpoints that predict clinical benefits are not yet established and until they are, we are concerned about their use as secondary endpoints unless the primary endpoint is also met.
Read More »On Medical Treatments & Products
Testimony of Dr. Diana Zuckerman About IV Tramadol Before FDA Advisory Committee
February 15, 2022: NCHR testifies against the opioid, tramadol, administered by IV to the FDA Advisory Committee.
Read More »Statement by Dr. Diana Zuckerman on Sintilimab at FDA Advisory Committee on Oncologic Drugs
February 10, 2022: NCHR president Dr. Diana Zuckerman testifies to the FDA Advisory Committee on Oncologic Drugs on Sintilimab.
Read More »NCHR’s Comments on Prediabetes and Type 2 Diabetes Screening for Children and Adolescents
January 18, 2022: We support the “I” recommendation against screening for either prediabetes or type 2 diabetes in asymptomatic children aged 18 years or younger.
Read More »Statement of Dr. Diana Zuckerman Regarding the January 11, 2022 CMS Decision about Aduhelm
January 11, 2022: Dr. Diana Zuckerman, president of NCHR, speaks in favor of CMS decision to limit coverage of the Alzheimer’s drug, Aduhelm.
Read More »